Cynata Therapeutics Limited (CYP.AX)
AUD 0.2
(5.41%)
AUD 0.2
(5.41%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 2.31 Million AUD | 68.49% |
| 2023 | 1.37 Million AUD | -81.65% |
| 2022 | 7.49 Million AUD | 491.62% |
| 2021 | 1.26 Million AUD | -81.19% |
| 2020 | 6.73 Million AUD | 554.38% |
| 2019 | 1.02 Million AUD | -6.08% |
| 2018 | 1.09 Million AUD | -25.44% |
| 2017 | 1.46 Million AUD | 79.36% |
| 2016 | 818.98 Thousand AUD | 186.77% |
| 2015 | 285.58 Thousand AUD | 1039.69% |
| 2014 | 25.05 Thousand AUD | -0.86% |
| 2013 | 25.27 Thousand AUD | 107.04% |
| 2012 | -359.02 Thousand AUD | -115.63% |
| 2011 | -166.49 Thousand AUD | 26.31% |
| 2010 | -225.95 Thousand AUD | -2131.44% |
| 2009 | -10.12 Thousand AUD | -150.69% |
| 2008 | 19.97 Thousand AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.4 Million AUD | 0.0% |
| 2024 FY | -280.73 Thousand AUD | -120.43% |
| 2024 Q4 | -370.43 Thousand AUD | 0.0% |
| 2023 Q2 | 1.66 Million AUD | 0.0% |
| 2023 Q4 | -286.67 Thousand AUD | 0.0% |
| 2023 FY | 1.37 Million AUD | -81.65% |
| 2022 Q2 | 6.83 Million AUD | 0.0% |
| 2022 Q4 | 659.56 Thousand AUD | 0.0% |
| 2022 FY | 7.49 Million AUD | 491.62% |
| 2021 Q2 | -112.49 Thousand AUD | 0.0% |
| 2021 FY | 1.26 Million AUD | -81.19% |
| 2021 Q4 | 1.37 Million AUD | 0.0% |
| 2020 Q2 | 4.3 Million AUD | 0.0% |
| 2020 FY | 6.73 Million AUD | 554.38% |
| 2020 Q4 | 2.42 Million AUD | 0.0% |
| 2019 Q2 | 1.3 Million AUD | 0.0% |
| 2019 FY | 1.02 Million AUD | -6.08% |
| 2019 Q4 | -140.23 Thousand AUD | 0.0% |
| 2018 Q4 | -77.14 Thousand AUD | 0.0% |
| 2018 FY | 1.09 Million AUD | -25.44% |
| 2018 Q2 | 1.45 Million AUD | 0.0% |
| 2017 Q4 | -25.39 Thousand AUD | 0.0% |
| 2017 Q2 | 1.77 Million AUD | 0.0% |
| 2017 FY | 1.46 Million AUD | 79.36% |
| 2016 Q2 | 1.01 Million AUD | 0.0% |
| 2016 Q4 | 87.34 Thousand AUD | 0.0% |
| 2016 FY | 818.98 Thousand AUD | 186.77% |
| 2015 FY | 285.58 Thousand AUD | 1039.69% |
| 2015 Q4 | 242.23 Thousand AUD | 0.0% |
| 2015 Q2 | 43.35 Thousand AUD | 0.0% |
| 2014 FY | 25.05 Thousand AUD | -0.86% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 Q2 | 25.05 Thousand AUD | 0.0% |
| 2013 Q3 | 6318.75 AUD | -75.0% |
| 2013 Q2 | 25.27 Thousand AUD | 128.16% |
| 2013 Q1 | -89.75 Thousand AUD | 0.0% |
| 2013 FY | 25.27 Thousand AUD | 107.04% |
| 2013 Q4 | - AUD | -100.0% |
| 2012 Q4 | - AUD | 100.0% |
| 2012 Q2 | -89.75 Thousand AUD | -115.63% |
| 2012 Q1 | -41.62 Thousand AUD | 0.0% |
| 2012 FY | -359.02 Thousand AUD | -115.63% |
| 2012 Q3 | -89.75 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | 100.0% |
| 2011 Q3 | -41.62 Thousand AUD | 0.0% |
| 2011 Q2 | -41.62 Thousand AUD | 26.31% |
| 2011 Q1 | -56.48 Thousand AUD | 0.0% |
| 2011 FY | -166.49 Thousand AUD | 26.31% |
| 2010 Q3 | -56.48 Thousand AUD | 0.0% |
| 2010 Q2 | -56.48 Thousand AUD | -2131.44% |
| 2010 Q4 | - AUD | 100.0% |
| 2010 Q1 | -2531.50 AUD | 0.0% |
| 2010 FY | -225.95 Thousand AUD | -2131.44% |
| 2009 Q2 | -2531.50 AUD | -150.69% |
| 2009 FY | -10.12 Thousand AUD | -150.69% |
| 2009 Q3 | -2531.50 AUD | 0.0% |
| 2009 Q1 | 4994.00 AUD | 0.0% |
| 2009 Q4 | - AUD | 100.0% |
| 2008 Q4 | - AUD | -100.0% |
| 2008 Q2 | 4994.00 AUD | 0.0% |
| 2008 FY | 19.97 Thousand AUD | 0.0% |
| 2008 Q3 | 4994.00 AUD | 0.0% |
| 2008 Q1 | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q2 | - AUD | 0.0% |
| 2007 Q3 | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | -53.566% |
| Acrux Limited | -1.28 Million AUD | 280.346% |
| Race Oncology Limited | 1.38 Million AUD | -66.603% |
| Biome Australia Limited | 7.66 Million AUD | 69.808% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 135.345% |
| BTC Health Limited | 16.36 Thousand AUD | -14054.297% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 68.933% |
| CSL Limited | 15.28 Billion AUD | 99.985% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 79.876% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 97.035% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 95.455% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 1.44 Million AUD | -60.374% |
| Memphasys Limited | 1606.00 AUD | -144086.986% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 98.871% |
| Noxopharm Limited | -534.81 Thousand AUD | 532.983% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 37.623% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 110.867% |
| Starpharma Holdings Limited | 7.65 Million AUD | 69.758% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -1438.521% |
| Biotron Limited | -40.49 Thousand AUD | 5817.919% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 39.142% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 409.202% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 868.171% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -22416.949% |
| Patrys Limited | 1.39 Million AUD | -66.096% |
| Orthocell Limited | 3.68 Million AUD | 37.219% |
| Imugene Limited | -5.83 Million AUD | 139.652% |
| PYC Therapeutics Limited | 22.05 Million AUD | 89.503% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 306.167% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 9013.519% |
| Nanollose Limited | -348.95 Thousand AUD | 763.599% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -91.019% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 2635.274% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 42.264% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -85.018% |
| Nyrada Inc. | -5164.07 AUD | 44941.433% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 99.249% |
| Dimerix Limited | 583.47 Thousand AUD | -296.869% |
| PharmAust Limited | -1641.00 AUD | 141211.7% |
| AnteoTech Limited | 460.39 Thousand AUD | -402.967% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -3975.975% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 731.365% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 5387.46% |
| Actinogen Medical Limited | 9.93 Million AUD | 76.684% |
| Immuron Limited | 3.33 Million AUD | 30.603% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 10.866% |